Lilly Wins Stay In Zyprexa Whistleblower Suit

Law360, New York (December 14, 2007, 12:00 AM EST) -- In a boost to Eli Lilly & Co., a federal judge has granted the pharmaceutical giant's bid to stay a whistleblower suit over charges it marketed its blockbuster anti-psychotic drug Zyprexa for off-label uses.

In an order handed down Thursday in the U.S. District Court for the Northern District of California, Judge Charles Breyer said that the interests of federal uniformity and judicial economy weighed in favor of a stay.

Lilly had argued that the case should be joined with a separate multidistrict product liability litigation...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.